Amunix Pharmaceuticals has appointed Maninder Hora to serve as chief technical operations officer, the same position he held at Nektar Therapeutics (NASDAQ: [[ticker:NKTR]]). Mountain View, CA-based Amunix is developing a type of cancer drug called a T cell engager using technology that the company says overcomes the limitations of these immunotherapies.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
